Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study
IBI389(一种抗Claudin18.2×CD3双特异性抗体)在实体瘤和胃或胃食管肿瘤患者中的安全性和初步疗效结果:一项1期剂量递增和扩展研究
期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-025-04597-8
Li, Xiaoyu; Dai, Ruihong; Xu, Qi; Guo, Zengqing; Hu, Changlu; Sun, Yuping; Niu, Zuoxing; Hao, Jihui; Zhang, Mingjun; Dai, Guanghai; Hua, Dong; Pan, Yueyin; Wang, Xin; Wei, Shuqing; Chen, Xiaobing; Wu, Qian; Zhang, Yulong; Zhou, Hui; Ying, Jieer; Zheng, Li; Bi, Feng